These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia. Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418 [TBL] [Abstract][Full Text] [Related]
33. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129 [TBL] [Abstract][Full Text] [Related]
34. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related]
35. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466 [TBL] [Abstract][Full Text] [Related]
36. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872 [TBL] [Abstract][Full Text] [Related]
37. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Donato NJ; Fang D; Sun H; Giannola D; Peterson LF; Talpaz M Biochem Pharmacol; 2010 Mar; 79(5):688-97. PubMed ID: 19874801 [TBL] [Abstract][Full Text] [Related]
38. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711 [TBL] [Abstract][Full Text] [Related]
39. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B. Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229 [TBL] [Abstract][Full Text] [Related]